Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran

The pharmacologic management of patients with high-risk coronary artery disease consists of aspirin and a P2Y12 receptor inhibitor. Chronic oral anticoagulation with warfarin is the major treatment strategy to attenuate thromboembolism or stroke in patients with deep vein thrombosis, pulmonary embolism, heart failure and atrial fibrillation. A substantial percentage of the latter group of patients have coronary artery disease and may require stenting with long-term dual antiplatelet therapy in addition to therapy with warfarin to reduce arterial ischemic events in addition to stroke. These new oral anticoagulants have been developed for long-term therapy to overcome the limitations of warfarin. Dabigatran is a direct thrombin inhibitor and its role in patients with acute coronary syndrome is being explored.

[1]  D. Prabhakaran,et al.  Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. , 2012, JAMA.

[2]  Deepak L. Bhatt,et al.  Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. , 2012, The New England journal of medicine.

[3]  Celeste B. Burness,et al.  Dabigatran Etexilate , 2012, Drugs.

[4]  P. Gurbel,et al.  Platelet Function Testing and Genotyping Improve Outcome in Patients Treated With Antithrombotic Agents , 2012, Circulation.

[5]  Adrian V. Hernández,et al.  Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. , 2012, Archives of internal medicine.

[6]  Paul Burton,et al.  Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[7]  F. Van de Werf,et al.  Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. , 2011, European heart journal.

[8]  Deepak L. Bhatt,et al.  Apixaban with antiplatelet therapy after acute coronary syndrome. , 2011, The New England journal of medicine.

[9]  P. Kirchhof,et al.  Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) a , 2010, European heart journal.

[10]  M. Feuring,et al.  Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity , 2010, Thrombosis and Haemostasis.

[11]  P. Gurbel,et al.  Combination Antithrombotic Therapies , 2010, Circulation.

[12]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[13]  J. Mega,et al.  Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial , 2009, The Lancet.

[14]  Deepak L. Bhatt,et al.  Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial , 2009, Circulation.

[15]  Salim Yusuf,et al.  Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[16]  G. Lip,et al.  Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation , 2008, Annals of medicine.

[17]  T. Orfeo,et al.  Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition , 2007, Journal of thrombosis and haemostasis : JTH.

[18]  J. Stassen,et al.  In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate , 2007, Thrombosis and Haemostasis.

[19]  M. Pfeffer,et al.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.

[20]  G. Biondi-Zoccai,et al.  Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. , 2006, European heart journal.

[21]  P. Gurbel,et al.  Platelet activation in myocardial ischemic syndromes , 2004, Expert review of cardiovascular therapy.

[22]  MassimoChiariello,et al.  Involvement of Tissue Factor Pathway Inhibitor in the Coronary Circulation of Patients With Acute Coronary Syndromes , 2003 .

[23]  W. Weaver,et al.  Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial , 2003, The Lancet.

[24]  L. Seipel,et al.  Relationship Between Minor Myocardial Damage and Inflammatory Acute-Phase Reaction in Acute Coronary Syndromes , 2003, Journal of Thrombosis and Thrombolysis.

[25]  H. Arnesen,et al.  Warfarin, aspirin, or both after myocardial infarction. , 2002, The New England journal of medicine.

[26]  D. Grobbee,et al.  Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial , 2002, The Lancet.

[27]  Frank M Szaba,et al.  Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. , 2002, Blood.

[28]  S. Pocock,et al.  A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. , 1999, The New England journal of medicine.

[29]  How-Ran Guo,et al.  Prognostic significance of elevated hemostatic markers in patients with acute myocardial infarction. , 1999, Journal of the American College of Cardiology.

[30]  S. Pocock,et al.  A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .

[31]  E. Fleck,et al.  Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. , 1998, Circulation.

[32]  J. Pogue,et al.  Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. , 1998, Circulation.

[33]  I M Morison,et al.  Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. , 1997, Journal of the American College of Cardiology.

[34]  D. Ardissino,et al.  Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[35]  D. Ardissino,et al.  Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[36]  D. Ardissino,et al.  Persistent Activation of Coagulation Mechanism in Unstable Angina and Myocardial Infarction , 1994, Circulation.

[37]  M. J. Winn,et al.  Argatroban and Inhibition of the Vasomotor Actions of Thrombin , 1993, Journal of cardiovascular pharmacology.

[38]  A. Ibrahim,et al.  Acute myocardial infarction. , 2014, Critical care clinics.

[39]  G. Lip,et al.  New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes , 2012 .

[40]  J. Weitz,et al.  Factor Xa and thrombin as targets for new oral anticoagulants. , 2011, Thrombosis research.

[41]  Deepak L. Bhatt,et al.  APPRAISE 2. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome for the APPRAISE-2 Investigators* , 2011 .

[42]  A. Kastrati,et al.  A RANDOMIZED COMPARISON OF ANTIPLATELET THERAPY AFTER THE PLACEMENT OF CORONARY ARTERY STENTS , 1996 .

[43]  R. Kronmal,et al.  Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. , 1994, Circulation.